clinical research company in dubai

Switch language:

• Analyst Comment

ICON tops list of most-used contract research organisations in 2024

ICON’s service portfolio includes adaptive trials, biosimilars, clinical research services, resourcing solutions and laboratory services.

• Share on Linkedin
• Share on Facebook

Contract research organisations (CROs) are companies that are contracted to provide support to pharmaceutical, biotechnology and medical device companies to successfully complete product development. This includes, but is not limited to, clinical trial operation, patient recruitment and the design of protocols. More than 500 clinical trials have been initiated in 2024 using a CRO, with ICON the most used.

ICON is a contract research organisation headquartered in Ireland that provides specialised services that span the entire lifecycle of product development. ICON’s service portfolio comprises adaptive trials, biosimilars, clinical research services, commercialisation and outcomes, consulting, provision of functional services, medical imaging, resourcing solutions and laboratory services, strategic support, and tactical solutions for traditional, in vitro diagnostic and software devices.

Go deeper with GlobalData

Immuno-oncology (IO) - Thematic Intelligence

Loa and ptsr model - icon-1 in choroidal neovascularization, data insights.

The gold standard of business intelligence.

Find out more

Related Company Profiles

More than 500 clinical trials have been initiated in 2024 using a cro.

68% of ICON clinical trials are currently ongoing, with the most recent commencing on 5 August 2024. The Phase I trial, A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants , will be sponsored by Belgian company UCB and is expected to end in November 2024.

The main drug candidate being tested is zilucoplan, an immunosuppressive agent formulated as a solution for the subcutaneous route of administration for the treatment of myasthenia gravis. The trial will look to enroll a total of 14 patients at the Pharmaceutical Research Associate Group BV, located in Groningen, the Netherlands.

ICON has three planned clinical trials for the last four months of 2024: Phase I trials for the treatment of ulcerative colitis and Covid-19, and a Phase II trial for the treatment of dengue fever.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

More Relevant

Clinical ink launches EDC platform for clinical trials

Merck kgaa doses first subject in phase iii generalised myasthenia gravis trial, gain therapeutics reports positive data from phase i parkinson's treatment trial, nih grants funds to establish network for nursing home trials, sign up for our daily news round-up.

Give your business an edge with our leading industry insights.

Sign up to the newsletter: In Brief

Your corporate email address, i would also like to subscribe to:.

I consent to Verdict Media Limited collecting my details provided via this form in accordance with Privacy Policy

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

• Hi, My Account Subscriptions --> My KT Trading Contact Us Privacy Notice Sign Out

Fri, Aug 30, 2024 | Safar 27, 1446

Dubai 20°C

• Expo City Dubai
• Emergencies
• Ras Al Khaimah
• Umm Al Quwain

Life and Living

• Visa & Immigration in UAE
• Banking in UAE
• Schooling in UAE
• Housing in UAE
• Ramadan 2024
• Saudi Arabia
• Philippines
• Cryptocurrency
• Infrastructure
• Currency Exchange
• Horse Racing
• Local Sports

Entertainment

• Local Events

Dubai World Cup

• Track Notes
• Big Numbers
• Daily Updates
• Arts & Culture
• Mental Health
• Relationships
• Staycations
• UAE Attractions
• Tech Reviews
• Motoring Reviews
• Movie Reviews
• Book reviews
• Restaurant Reviews
• Young Times

Supplements

• Back To School
• Eid-Al-Adha
• It’s Summer Time
• Leading Universities
• Higher Education
• India Real Estate Show
• Future Of Insurance
• KT Desert Drive
• New Age Finance & Accounting Summit
• Digital Health Forum
• Subscriptions
• UAE Holidays
• Latest News
• Prayer Timings
• Cinema Listings
• Inspired Living
• Advertise With Us
• Privacy Notice

KT APPDOWNLOAD

Dubai corporates outpace GCC listed peers

Dfm-listed companies’ q2 profit surges 32% to $6.1b.

• Follow us on

Top Stories

UAE announces 2-month grace period for residence visa violators

UAE announces fee refund for tax service charges from August 1

Paid parking in Dubai: Residents face up to Dh4,000 extra yearly costs when new rates kick in

Published: Thu 29 Aug 2024, 6:02 PM

Net profits for Dubai-listed companies rose 30.9 per cent year-on-year to $6.7 billion in sthe econd quarter of 2024 against $5.1 billion in Q2 2023, marking a growth far outpacing aggregate net profit surge of 5.7 per cent posted by listed corporates across the GCC.

Dubai reported the second-biggest y-o-y growth in profits (after Bahrain) during Q2 2024 mainly related to accounting adjustments and restructuring implemented by DSI.

Earnings growth in Q2 was mainly driven by Dubai-based banks, capital goods and telecom companies, with the three sectors accounting for 83.1 per cent of the total earnings during the quarter.

Junaid Ansari, head of Investment Strategy & Research at Kamco, said out of Dubai Financial Market’s 13 sectors, seven have witnessed a y-o-y increase in profits during Q2 2024 while the remaining six sectors, including the insurance and diversified financial sectors, reported declines.

In terms of first half performance, net profits increased by 20 per cent y-o-y to reach $12.1 billion as compared to $10 billion in the first half of 2023. Total net profits for the banking sector rose by 12 per cent y-o-y in Q2 2024 to reach $3.3 billion, up from $2.9 billion in Q2 2023. The sector’s profits in the first-half increased by 13.9 per cent y-o-y to reach $6.5 billion, up from $5.7 billion in 1H-2023.

The banking sector’s rise in total earnings was primarily driven by Emirates NBD which delivered a record H1 profit of Dh13.8 billion driven by 13.6 per cent y-o-y profits growth during Q2 2024. The bank’s Q2 2024 profits reached $1.9 billion compared with $1.7 million during the corresponding period of 2023, driven by increased lending across the bank’s regional network coupled with substantial impaired loan recoveries during the period. The sector’s total earnings were also supported by Emirates Islamic Bank which reported its highest ever half year profit that reached Dh1.7 billion during 1H-2024.

Aggregate profits for the capital goods sector jumped nearly 11 times during Q2 2024 to reach $1.2 billion as compared to $101.5 million in Q2 2023. The sector’s jump in net earnings was mainly due to profits reported by Drake and Scull, which announced $1.0 billion in Q2 2024 net profits as compared to $11.8 million loss in Q2 2023. The company reported its first positive near profits in over six years after restructuring its debts. On the other hand, National Central Cooling and Dubai Investment Company reported 4.5 per cent and 8.7 per cent y-o-y growth in net earnings that reached $42.7 million and $78.7 million, respectively.

Total net earnings for listed real estate stocks in Dubai increased by 29 per cent y-o-y in Q2 2024 to $1.1 billion as compared to $859.2 million in Q2 2023 after all the constituent companies that comprise the sector reported y-o-y growth in their net profits during the period. First-half net earnings for the sector witnessed 11.9 per cent y-o-y growth to reach $2.4 billion versus $ 2.1 billion in 1H-2023. “Emaar Properties’ robust performance was the primary driver of the sector’s strong performance during the period. Q2 2024 net profits for the company increased by 39 per cent y-o-y to reach $658.7 million as compared to $473.7 million in Q2 2023 while its 1H-2024 net profits edged up 8.0 per cent y-o-y to reach $1.5 billion. Listed companies in Abu Dhabi witnessed a 4.7 per cent y-o-y uptick in total net profits during Q2 2024 to reach $8.3 billion as compared to $7.9 billion during Q2 2023. On the other hand, total net profits declined by 2.2 per cent y-o-y during the first half of 2024 to reach $16.2 billion down from $16.5 in the first half of 2023.

Combined net profits reported companies listed on GCC exchanges witnessed a healthy y-o-y growth of 5.7 per cent during Q2 2024 led by a broad-based growth across most markets in the region, barring Oman. The q-o-q growth came in at 8.1 per cent with total net profits up for the second consecutive quarter to reach $60.7 billion during Q2 2024 as compared to $56.2 billion in Q1-2024 and $57.4 billion in Q2 2023.i

• [email protected]

More news from Business

Several uae residents now own digital currencies as nation ranks third in crypto adoption globally.

Cryptocurrency usage has been growing across different sectors such as retail, real estate and others

business 2 days ago -->

2 new Salik gates: Company to pay Dh2.73 billion to RTA for new toll gates

The Business Bay Gate is valued at Dh2.265 billion and the Al Safa South Gate valued at Dh469 million

Spain blocks Hungarian takeover bid for train maker Talgo

Orban has been at loggerheads with Brussels for years over rule of law issues

business 3 days ago -->

UAE leads in Q2 gross loan growth as GCC banks’ net profit surges to $14.8b

Aggregate net profits reached $14.8 billion during the quarter

Hindenburg Research discloses short position in server maker Super Micro

The company's shares have nearly doubled this year, after more than tripling in 2022, outperforming even Nvidia

Cooling inflation raise hopes for interest rate cut in India

Good monsoon is expected during September, boosting farm output

UAE: Web3 streaming platform myco raises $10 million for its Series A funding

Last month, myco reported its first profitable year, with an EBITDA of $1 million and revenue of $7.5 million for the 2023-24 fiscal year

UAE: Emirati women own over 128,000 businesses in SME sector, minister says

The number of commercial licences issued to UAE female nationals grew by 23 per cent from January to August 26 across various sectors

Type your keywords

• Molecular Partners-stock
• News for Molecular Partners

Molecular Partners’ Hold Rating: Balancing Drug Development Progress and Uncertain Clinical Timelines

Molecular Partners ( MOLN – Research Report ), the Healthcare sector company, was revisited by a Wall Street analyst on August 28. Analyst Daina Graybosch from Leerink Partners maintained a Hold rating on the stock and has a $6.00 price target.

Daina Graybosch has given his Hold rating due to a combination of factors, including the current status and future expectations surrounding Molecular Partners’ drug development programs. While there is a renewed sense of optimism for the potential of MP0533 in treating acute myeloid leukemia (AML), critical clinical data that could significantly pique the interest of institutional investors is not anticipated until the latter part of 2025 or 2026. This delay in obtaining influential results contributes to a cautious stance on the stock. Additionally, the discussions from the first half of 2024 earnings call highlighted the ongoing development of the Radio-DARPin platform and clarified the expected timelines for both the MP0712 program and collaborations with other companies. Despite progress in dose optimization and a hypothesis that could lead to improved drug efficacy, there remains a level of uncertainty due to the rapid clearance of MP0533 observed during dose escalation. The company’s financial position is solid, with funds projected to last into 2027, but the substantial clinical data needed to drive the stock higher is still on the horizon.

MOLN’s price has also changed dramatically for the past six months – from $4.300 to $6.330, which is a 47.21% increase.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Molecular Partners (MOLN) Company Description:

Molecular Partners AG is a clinical-stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company’s product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Read More on MOLN:

• Molecular Partners Advances Therapeutic Platforms
• Molecular Partners Reports H1 2024 Corporate Highlights and Financials
• Molecular Partners AG (ADR) trading resumes
• Molecular Partners AG (ADR) trading halted, volatility trading pause

Molecular Partners News MORE

Related Stocks

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Biden Economy
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds Rates
• Top Mutual Funds
• Options: Highest Open Interest
• Options: Highest Implied Volatility
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Stock Comparison
• Advanced Chart
• Currency Converter
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Credit Card Offers
• Best Free Checking
• Student Loans
• Personal Loans
• Car insurance
• Mortgage Refinancing
• Mortgage Calculator
• Morning Brief
• Market Domination
• Market Domination Overtime
• Asking for a Trend
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Financial Freestyle
• Capitol Gains
• Living Not So Fabulously
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Xortx highlights pioneering research indicating a role for genetic regulation of xanthine oxidase and therapeutic targeting of aberrant purine metabolism.

● Xanthine oxidase reported to modulate progression of chronic kidney disease, diabetic kidney disease, polycystic kidney disease, and other indications ●

CALGARY, Alberta, Aug. 29, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to report that recent peer-reviewed, independent, published research highlights that genetic factors are linked to the over-expression of xanthine oxidase (“XO”) and play a role in several diseases, including kidney disease. These ground-breaking findings further support the Company’s approach to treating kidney and other diseases by inhibiting XO.

Xanthine oxidase is an essential enzyme within the uric acid metabolic pathway and is required for the breakdown of purine nucleotides. The breakdown products of XO, including uric acid (“UA”) and reactive oxygen species (“ROS”), are released during the enzymatic reaction and may play a detrimental role in the circulatory system and within tissue during disease. XORTX sponsored discoveries in rodent models of polycystic kidney disease (“PKD”) implicate over-expression or over-activity of XO as a potentially important target in treating this disease.

Evidence for over-expression of XO in human PKD has not been reported to date, although work by Wang et al. suggests linkage of genetic factors to PKD 1 . Recently, new emerging discoveries link genetic factors to specific populations and show that higher XO expression is associated with a variety of conditions including hyperuricemia 2 , sepsis, organ failure and sepsis associated acute respiratory distress syndrome (ARDS) 3,4 , kidney dysfunction 3,4 , diabetes 5 , PKD 1,5 and kidney failure 6,7 . From a mechanistic standpoint, these studies advocate for a precision-medicine approach in which genetic risk variants would guide treatment decisions 1 .

Commenting on the research, Allen Davidoff, Ph.D., CEO of XORTX, stated, “The combination of pioneering research in autosomal dominant polycystic kidney disease (“ADPKD”) sponsored by XORTX and these peer-reviewed, published research papers support our belief that pharmacologic targeting of XO holds enormous therapeutic potential, specifically where increased XO activity is associated with non-diabetic or diabetic kidney diseases. These discoveries highlight an opportunity to develop a personalized therapeutic approach for individuals whose unique genetic factors predisposed them to disease, and the need for xanthine oxidase inhibition to treat those individuals at risk. We believe that XORTX’s expertise in developing XO inhibitors, protected by a patent portfolio that anticipated this opportunity, combined with our therapeutic platform is ideally positioned to deliver targeted therapeutics to individuals. Our planned clinical trial in patients with ADPKD will test XORLO™, our proprietary formulation of oxypurinol, and will also provide an opportunity to further understand the role of these newly identified genetic factors in individuals with PKD.”

References:

Korsmo HW, Emerging roles of xanthine oxidoreductase in chronic kidney disease, Antioxidants, June 2024

Major TJ, et all, Evaluation of the diet wide contribution to serum urate levels: Met-analysis of population based cohorts, BMJ, 363, k3952, 2018

Gao, Li et al., Xanthine oxidoreductase gene polymorphism are associated with high risk of sepsis and organ failure, Respir. Res, 24, 177_2023

Liu H, et al., Genetic variants in XDH are associated with prognosis off gastric cancer in a Chines population, 663, 196, 2013

Wang et al., Genetic susceptibility to diabetic kidney disease is linked to promoter variants of XOR, ” The authors identified an expression quantitative trait loci (QTL) in the  cis -acting regulatory region of the xanthine dehydrogenase, or xanthine oxidoreductase (XO), a binding site for C/EBPβ, to be associated with diabetes-induced podocyte loss in diabetic kidney disease in male mice. They concluded that certain types of alleles of a gene that controls the expression of xanthine oxidase can be over expressed in CKD, diabetic kidney disease and polycystic kidney disease.

Kudo M et al., Functional Characterization of Genetic Polymorphisms Identified In the Promotor Region of the Xanthine Oxidase Gene, Drug Metab. Pharmacokinet., 25, 599, 2010

Boban M, et al., Circulating purine compound, uric acid, and xanthine oxidase/dehydrogenate relationship in essential hypertension and end stage renal disease., Ren. Fail., 36, 613, 2014

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com .

For more information, please contact:

Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward Looking Statements

This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca .

• Skip to content
• Skip to footer
• Our Stories

• Drug Ordering for Pharmacies
• Specialty Drugs for Physician Practices
• Plasma & Biologics for Non-Physicians
• Brand Name Drugs
• Generic Drugs
• OTC Pharmacy Products
• Controlled Substance Ordering (CSOS)
• Drug Packaging Solutions
• Post Acute Care Supplies
• Surgery Center Supplies & Equipment
• Physician Supplies
• Non-Acute Supplies
• Lab Supplies & Equipment
• Home Medical Equipment
• Emergency Medical Products
• Flu Vaccines
• SupplyManager Medical Supply Ordering
• Pharmacy Ownership Consulting
• Health Mart Franchise Program
• Consulting & Software Solutions
• Prescribed Perspectives
• Health Mart Atlas
• McKesson Specialty Network
• Pharmacy Management Software
• Pharmacy Operations
• Pharmacy Automation Solutions
• Drug Purchasing Management
• Pharmacy Group Purchasing
• Pharmacy Claims Reimbursement
• Audit Risk Mitigation
• Patient Adherence & Wellness
• Alternate Site Pharmacy Solutions
• Specialties We Support
• Drug Purchasing and Management
• Advisors and Tools
• Technology Solutions
• Oncology Clinical Management Technology
• Full-Service Practice Management
• Distribution Services
• Third Party Logistics
• Clinical Trials Services
• Specialty Pharmacy
• Oncology Real-World Evidence & Provider Engagement
• Access & Adherence
• Program Pharmacy
• LoyaltyScript Co-Pay Program
• eVoucherRx Co-Pay Savings

About McKesson

• Press Releases

McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute’s Core Ventures

August 26, 2024

Acquisition enhances McKesson’s integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network

IRVING, Texas, August 26, 2024 — McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures.

McKesson will purchase its controlling interest for approximately $2.49 billion in cash, which will represent approximately 70% ownership. Following completion of the transaction, Core Ventures will be part of the Oncology platform, and financial results will be reported within McKesson’s US Pharmaceutical segment. The transaction is subject to customary closing conditions, including necessary regulatory clearances. Following the close of the transaction, FCS , a practice with more than 250 physicians and 280 advanced practice providers, across nearly 100 locations in Florida, will remain independently owned and FCS will join McKesson’s The US Oncology Network (The Network), a leading oncology organization, dedicated to advancing local and affordable cancer care and better patient outcomes.

“This milestone marks an important step forward in our efforts to advance community-based oncology care,” said Brian Tyler, chief executive officer, McKesson. “By growing our Oncology platform, we will bring advanced treatments and improved care experiences to patients, while also reducing the overall cost of care. FCS and Core Ventures’ expertise and patient-first approach align with our commitment to accelerating clinical development, improving patient outcomes, and expanding access to quality cancer care in the community. We are also pleased to welcome Florida Cancer Specialists & Research Institute to The US Oncology Network, reinforcing our dedication to empowering community-based providers to independently thrive in today’s rapidly evolving healthcare landscape.”

FCS has provided exceptional care to cancer patients for over 40 years. During that time, services have grown to include clinical trials, diagnostic imaging, medical oncology and chemotherapy infusion, integrative therapy, molecular and pathology lab services, radiation oncology, next-generation sequencing, medically integrated dispensing, and data services. FCS currently conducts clinical trials through Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials. By joining The Network, FCS will have access to McKesson’s differentiated Oncology platform , including best-in-class oncology care products and services.

“Above all else, our patients are the true beneficiaries of this transaction, as we seek to drive meaningful outcomes and deliver sustained value with every interaction. Through the power of our combined operational expertise, we can bolster community oncology's role in increasing access to high-quality, affordable care,” said Lucio N. Gordan, MD , president and managing physician, FCS .

“This is a historic moment for FCS and reflects the evolution of our practice and the forward-thinking of physician leadership, our board, and the entire organization at large,” said Nathan H. Walcker , chief executive officer of FCS . “The US Oncology Network and FCS share a mission and we both aim to strengthen patient-centered cancer care in the community to improve outcomes. We are thrilled to partner with McKesson and join The Network, which furthers the joint commitment to bringing the best medicine and innovation for patients into communities across Florida.”

Cautionary Statements

Except for historical information, statements in this press release regarding McKesson’s proposed acquisition and related arrangements constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements. We encourage investors to read the important risk factors described in the company’s most recent Form 10-K filed with the Securities and Exchange Commission. These risk factors include, but are not limited to: we may be unable to obtain necessary regulatory approvals; we may not achieve expected outcomes from the transaction; we might be adversely impacted by delays or other difficulties, including related to the transactions described in this press release; we from time to time record significant charges from impairment to goodwill, intangibles and other assets or investments; we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, economic events and other catastrophic events.  

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories .

About McKesson Oncology and Specialty Solutions

It’s an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson , our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care.

• McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture with  Sarah Cannon Research Institute .
• The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers.
• Ontada ® , a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care.
• As one of the largest distributors of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them.
• And through CoverMyMeds , Biologics by McKesson , and GPO services , our work continues to help patients access, afford, and adhere to their medicines.

Rachel Rodriguez Investors 469-260-0556 [email protected]

Claire Crye Media 281-825-9927 [email protected]

You are using an outdated browser. Please upgrade your browser to improve your experience.

Latest News

RAY CRO is pleased to announce the latest publication of an article entitled “Level of Agreement and Correlation Between the Estimated Hemoglobin A1c Results Derived by Continuous or Conventional Glucose Monitoring Systems

publication of an article entitled “Level of Agreement and Correlation Between the Estimated Hemoglobin A1c Results Derived by Continuous

Level of Agreement and Correlation Between the Estimated Hemoglobin A1c Results Derived by Continuous or Conventional Glucose Monitoring Systems Compared with the Point-of-Care or Laboratory-Based Measurements: An Observational Study

Evaluation of Patient Satisfaction and Clinical Efficacy of Using Blood Glucose Meters Featuring Color-coded Indicators in Patients with Type 1 Diabetes: An Observational Hospital-Based Study

Publication: Screening and Treatment Program to Eliminate Hepatitis C in Egypt

• Our Leadership
• Terms & Conditions
• Privacy Policy

IROS leads the way as a groundbreaking, UAE-based CRO, driving excellence in clinical research. Our focus on real-world evidence and comprehensive clinical trials spans across all therapeutic domains .

Our mission is to leverage cutting-edge technologies to pioneer health innovation and advance excellence in clinical research and real-world evidence. IROS is dedicated to improving patients’ lives and shaping the health landscape by conducting high quality research and achieving groundbreaking insights.

Our Services

IROS offers precision-driven research solutions for all clinical research projects:

Regulatory Affairs

Real-world evidence, quality assurance, clinical operations, data management.

Our team of regulatory experts serves as your gateway to successful regulatory submissions, ensuring robust communication with authorities, meticulous compliance with labelling and packaging requirements, and overall adherence to clinical research standards.

Our specialized team ensures precision, compliance, and excellence, from regulatory submissions to impactful manuscripts, magnifying the influence of your medical innovations.

IROS specializes in assuring the highest quality throughout your clinical trials, from meticulous audits to expert guidance in preparing for regulatory inspections.

We specializes in orchestrating all aspects of clinical research, spanning from crucial study initiation and site selection to effective project and site management.

IROS’s dedicated team specializes in harnessing the power of data to ensure that your research is robust, reliable, and impactful. Whether it's through data management and consultancy or cutting-edge biostatistics, we empower your research with insights that matter.

Access to exclusive services for pioneering research

Biobanking services.

Elevate your research and generate significant data with our expertise in biobanking service

AI Supported Services

Accelerate your milestones with AI precision using our services and deliver accurate and impactful scientific communication.

Omics Technologies

Foster groundbreaking and insightful scientific discoveries using our unrivalled access to the latest the omics tools and technologies. 

Clinical and Laboratory Services

Optimize clinical operations using our pioneering and state-of-the-art clinical site and laboratory services.

Why Choose IROS?

Access to leading facilities, expert personnel, quicker turnaround times, rigorous internal quality management , collaboration.

Our commitment to collaboration fosters synergy among our team, clients, and partners, driving healthcare innovation to new heights.

Our unwavering commitment is the foundation of our success. We are resolute in our pursuit of healthcare advancement, ensuring every task is executed with precision and diligence.

Innovation is in our DNA. We continually seek new horizons in clinical research and real-world evidence generation, harnessing the power of technology and collective creativity.

Precision defines our approach and is echoed in every facet of our work. This commitment to precision means each task is executed with meticulous attention to detail and accuracy.

Partner with us to drive innovation in clinical research and real-world evidence studies. Together, we will transform healthcare.

Partner with iros, other assets.

Your destination for world-class complex care. Ranked UAE and GCC’s number one hospital in Newsweek’s 2023 ‘World’s Best Hospitals’ list.

World-class specialty women and children’s hospital in the Emirate of Abu Dhabi.

World’s 3rd Largest Dialysis Provider.

The region’s leading fertility network, with highly specialized and experienced Reproductive Health and IVF experts providing tailored treatment plans i...

Provider of premium specialized outpatient care in the United Arab Emirates and Saudi Arabia.

Multi-specialty hospital combining international standards and the latest innovations with a boutique hospitality experience.

Global leader in diabetes treatment, education, and research.

World-leading

Specialty Clinic & Day Surgery Center.

Committed to bringing world-class diagnostic testing to the UAE and the region.

Leading provider of long-term care and rehabilitation in the Middle East. Pioneer in post-acute care services in the GCC region.

Health screening provider in Abu Dhabi.

Committed to excellence in clinical genetic testing. The state-of-the-art laboratory specializes in advanced disease predisposition diagnostics and prov...

Leading AI-powered healthcare technology company.

Strategic initiative of the Department of Health – Abu Dhabi

The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate ...

PDC-CRO is a full-service contract research organization offering a broad range of early to late phase drug development services managed by professionals fully devoted to the clients’ programs and needs. The services can be contracted as part of a full-service integrated program or as stand-alone customized solutions. PDC works in close partnership with our clients to maximize opportunities, while maintaining flexibility to individual requirements and delivering key milestones on time and on budget.

PDC is a regional contract research organization, founded in 2011 and offering a Full-Service End-to-End innovative Solutions for your Phase I to IV clinical trials and NIS /RWE studies in the Middle East and Africa region. PDC-CRO offers direct access to 15+ MEA countries, in line with global standards and local cultures and regulations. Our international experience, as well as our proven track record of successful trials since 2011 assures our clients that PDC-CRO is their reliable partner for the MEA region. Our partners are comprised of an elite portfolio of clients including pharmaceutical corporations, biotechnology corporations, medical devices companies, global CROs, and academic institutions. Our team consists of 100+ employees experienced in managing clinical projects from start-up to completion with a pool of expertise. PDC is currently recognized among the leaders of Clinical Research Organizations in the region.

Our Services

Providing the full range of phase i to iv clinical development services..

Pharmaceutical Development Company is a full-service Contract Research Organization, dedicated to providing Clinical Research Solutions and Services across the MEA region.

Site Management and Coordination

Health Economics

Clinical outsourcing, clinical operations, medical writing, regulatory services, data science, biostatistics, clients testimonial.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam et, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Patient patient whose heart stopped beating for 50 minutes

Keep upto date with our blogs

January 10, 2021

The MEA region

January 18, 2021

1000 Volunteers have been enrolled

February 22, 2021

The Middle East and Africa region

March 22, 2021

For the Covid-19 Trials in the MEA region.

For Individuals

• Rehabilitation
• Specialized Treatment Programs

For Corporates

• Employees Assistance Program (EAP)
• Smoking Cessation Program
• Stress Debriefing & Critical Incident Stress Management
• Training & Awareness Programs

For Health Professionals

• Continuous Medical Education
• Patient Referral
• Our Clinicians
• Health Education Center

Clinical Research

• Latest ACPN Media Mentions
• Patient Experience

الخط الساخن:   800 ACPN[2276]

• Dr. Taoufik Alsaadi (ACPN, Chair)
• Prof. George Tadros (ACPN, Vice-Chair)
• Mr. Ahmed Mostafa (ACPN)
• Ms. Rana Abounakad (ACPN)
• Dr. Saqib Latif (ACPN)
• Dr. Tarek Shahrour (Sheikh Khalifa Medical City)
• Dr. Ahsan Khandoker (Khalifa University)
• Dr. Khaled Kadry (Maudsley Health Abu Dhabi)
• Dr. Lamya Turkawi (Sheikh Khalifa Medical City)
• Ms. Hajir Elbarrawy (ACPN)
• Ms. Reem Suliman (ACPN)

3. Research Collaborations:

a. Academic and Scientific Research Institutions:

Khalifa University, Abu Dhabi

Zayed University, Abu Dhabi

New York University Abu Dhabi

Harvard Medical School Center for Global Health Delivery – Dubai

Imperial College London Diabetes Centre (ICLDC) – Abu Dhabi

b. Current Pharmaceutical supporters

Biogen, Inc®

4. Guidelines for Proposed Research Studies:

No restrictions on the type of research that can be conducted as long as:

• Goal is justified and implications are identified
• Ethical considerations are met and conduct complies with guidelines of ICH – GCP and DOH Standard Operating Procedures (SOPs)
• Principal investigator meets requirements and has expertise in the study field

Note on clinical trials:

• Products/drugs must be registered with:
• The Ministry of Health Drug Control Department and DOH Medical Products Regulation Section
• Application fees apply

Note: investigational medicinal product is one that has been given marketing authorization but is being investigated for uses other than what is indicated. Does not apply to Phase 1 trials.

5. Criteria for Research:

Proposed studies must meet the following criteria: Benefit:  Does the proposed study have clear benefits to the community in which it is conducted? Effectiveness:  Will the study be effective in achieving the desired goal? Necessity:  Is the study necessary to achieve the goal or is there an alternative that won’t infringe on a competing value? Proportionality:  Is the desired goal important enough to justify overriding another principle or value? Least infringement:  Is the study designed to minimize infringement on the values that conflict with it? Transparency:  Is the Primary Investigator prepared to publicly justify their decision?

6. Ethical Considerations:

Ethics regarding human subjects: Respect for persons:  respect autonomous choices; protect those lacking autonomy Obtain informed consent from those capable of giving consent, proxy consent Beneficence:  do not harm; maximize benefits, minimize harms Risk/benefit assessment is conducted, clear action if adverse effects arise Justice:  fairness in distribution; treat equals equally Recruitment of subjects is fair, vulnerable populations not simply targeted out of convenience

7. Research Ethics Application: What to include

• ACPN ethics review application form  ( download form )
• Detailed study protocol  ( download form )
• Questionnaires and description of drugs/products that will be used (Arabic and English)
• Subject consent form (Arabic and English)
• Subject information sheet (Arabic and English)
• CVs of all investigators
• Investigators’  certification of Research Ethics Training for Protecting Human Research Participants

8. Application Submission Procedures:

• All ethics proposals are submitted to the IRB coordinator ( [email protected] ) , who reviews the application for completeness and confirms to investigators within five days of its receipt
• The IRB is required to give an ethical opinion on an application within 60 calendar days of the receipt of a valid application. Where the IRB considers that further information is required in order to give an opinion, the IRB may make one request in writing for further information from the applicant. The period of 60 days will be suspended pending receipt of this information
• In the case of a clinical trial involving a medicinal product for somatic cell therapy, the normal statutory time limit for review is extended to 90 days. This may be extended by a further 90 days (i.e. to 180 days in total) where the REC needs to consult a specialist group or Committee about the application

9. Ongoing Clinical Research Studies:

• Observational study to collect information on the safety and drug utilization of Fampyra® – Dr. Taoufik Alsaadi and colleagues
• A Pilot study on the prevalence of depression and anxiety among neurology patients attending ACPN – Dr. Ahmed Mohamed and colleagues
• Narcolepsy in the UAE: A Case series – Dr. Khaldoun Mozahem and colleagues
• Real world retrospective study of effectiveness and safety of Gilenya (Fingolimod®) in relapsing remitting Multiple Sclerosis in the Middle East and North Africa (FINOMENA) – Dr. Taoufik Alsaadi
• Repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of major depressive disorders: results from the UAE – Ms. Seada Kassie and Dr. Taoufik Alsaadi
• A comparison study of the use of Haptic Handwriting Tool among children with learning difficulties in the UAE – Dr. Samra Tahir and Dr. Mohamad Eid
• Can combined endurance and resistance training slow disease progression in adults with relapsing remitting multiple sclerosis? A pilot study – Ms. Helen Hughes and colleagues
• A cohort study on treatment outcome of anorexia nervosa in the UAE – Ms Carine El Khazen and colleagues
• Investigating the role of sleep-disordered breathing and its treatment on depressive symptoms in the UAE – Dr. Khaldoun Mozahem and colleagues
• Antiepileptic drugs use and major congenital malformation rate: A prospective observational cohort study: The United Arab Emirates – Dr. Taoufik Alsaadi and colleagues
• Patient cost-sharing for ambulatory neuropsychiatric services in Abu Dhabi, UAE  – Dr. Yousef Abouallaban and colleagues
• Potential factors impacting health-related quality of life among patients with epilepsy: Results from the United Arab Emirates  – Dr. Taoufik Alsaadi and colleagues
• Depression and anxiety as determinants of quality of life in patients with multiple sclerosis: The United Arab Emirates – Dr. Taoufik Alsaadi and colleagues
• Suicidal ideation Is associated with altered variability of fingertip photo-plethysmogram signal in depressed patients – Dr. Yousef Abouallaban and colleagues
• The rapidly changing landscape of multiple sclerosis immunomodulatory therapy a retrospective chart review in The United Arab Emirates  – Dr. Taoufik Alsaadi and colleagues
• Impact of working memory and cognitive functioning on specific language impairment (SLI)  – Dr. Samra Tahir and colleagues
• Working memory in children with intellectual disability (ID)  – Dr. Samra Tahir and colleagues

For more information, please send an email to  [email protected] or call +(971-2)-492-6000.

Board Members

Dr. Taoufik Alsaadi

Prof. George Tadros

ACPN offers quality mental health services with utmost care

Dubai, Dubai United Arab Emirates AMICULUM is an independent family of 11 branded agencies that deliver communications and consultancy services to pharmaceutical, biotechnology and health technology companies across the world. What makes us different is our agile and highly collaborative approach, which allows us to put together the right expertise from across our business to deliver high-quality, technically accurate and compelling content for different audiences, through the selective use of key communication channels. AMICULUM has grown steadily since 2001 with significant repeat business from our clients and recommendations from the leading experts we have worked with. We now have a team of over >350 healthcare communications professionals based in Europe, Asia-Pacific, MENA, and the USA.

P.O. Box 72900 Abu Dhabi United Arab Emirates Biocon Pharmaceuticals offers synthetic chemistry, molecular biology, and APIs.

Dubai HealthCare City P.O. Box 505176 Dubai United Arab Emirates Biocon Pharmaceuticals offers synthetic chemistry, molecular biology, and APIs.

Office # 205, Building C/P 72, Dubai Healthcare City, Dubai, United Arab Emirates ClinArt provides clinical project management, monitoring, quality assurance, and patient recruitment.

Dubai, Dubai United Arab Emirates Clinical Pathology Services offers histopathology, cytopathology, serology, hematology, biochemistry, and microbiology services.

32, MARASI DRIVE STREET BUSINESS BAY 177-0 DUBAI, DUBAI, 2534686829 United Arab Emirates We specialize in curating a diverse collection of specimens, primarily Formalin-Fixed Paraffin-Embedded (FFPE) blocks, enriched with a range of valuable features. Our biobank houses a meticulously cataloged assortment of FFPE blocks, each accompanied by comprehensive pathology reports along with Tumour and Necrosis Percentage. These blocks serve as a foundational resource for conducting a variety of research studies and diagnostic investigations. For those seeking a deeper understanding of genetic insights, we offer FFPE blocks with mutation analysis. These specimens undergo thorough genetic characterization, enabling researchers to delve into the intricate molecular landscape of each sample. Our cutting-edge Next-Generation Sequencing (NGS) Data Analysis further empowers investigators to uncover hidden genetic information, contributing to a more nuanced comprehension of disease mechanisms. In addition, we provide FFPE blocks that have undergone Polymerase Chain Reaction (PCR) and Fluorescence In Situ Hybridization (FISH) assays. These tested and reported specimens offer a targeted perspective, allowing researchers to explore specific genetic markers and structural alterations with high precision. One of the unique offerings of our biobank is the availability of Tissue specimens. This paired resource is a treasure trove for longitudinal studies, enabling researchers to correlate molecular changes in tissue samples with corresponding changes in plasma, offering insights into disease progression and treatment response. At our pathology lab biobank, we are committed to advancing medical and scientific knowledge by providing a range of high-quality specimens and associated data. Whether you're engaged in cancer research, biomarker discovery, or therapeutic development, our diverse collection is designed to catalyze your investigations and drive progress in the field of pathology and beyond. • We offer FFPE blocks with NGS mutation analysis. • FFPE blocks that have undergone Polymerase Chain Reaction (PCR) and Fluorescence In Situ Hybridization (FISH) assays.

Dubai, Dubai United Arab Emirates As a leading CRO, Europe, Middle East & Africa Clinical Research (EMEACR) is a dynamic full service clinical research organization in the EMEA region that has developed significant expertise to assist clients in the pharmaceutical, biotechnology and medical device industries to expedite time-to-market, in order to bring safe and effective treatments to the global marketplace for the patients who need them.

P.O. Box : 4184 - Ajman, United Arab Emirates

Executive Office No. 103, Building No. 3, 1st Floor, Dubiotech Business Centre, Academic City, Dubai United Arab Emirates Getz Pharma Research offers impurity profiling, stability testing, API, formulation development, characterization, and screening services.

United Arab Emirates Genetrics along with their partners represent a diverse set of technical and scientific capabilities. We help hospitals, research labs, universities, forensic labs, environment labs, food and drug control labs and genome centre labs to design large scale projects and provide reference testing services. We associate with leading institutions and laboratories to provide Diagnostics and Genomics Reference testing services, which include Microarray, Next Generation Sequencing (NGS) and Bioinformatics services to domestic / international pharma, biotech companies and academia.

Dubai Silicon Oasis, DDP, Building A1 Dubai, Dubai, 000000 United Arab Emirates IBS GL is a fast-growing CRO with a network of clinical sites, facilitating access to a wide range of biospecimens. Our clinical network encompasses medical doctors, research groups, hospitals, and testing labs. Our project office can assist in formulation of a technical task, and provide tailored biomaterial collections.

1318, F13, OQ3, DSP - South Tower, Dubai Science Park Dubai, Dubai, 00000 United Arab Emirates Modeling and Simulation Decisions FZ LLC is an independent modeling consultancy. Our objective is to provide model-informed drug development solutions for global pharmaceutical companies and biotech start-ups. • We support decisions-making across the entire R&D pipeline by addressing the recurring questions on compound selection, dose & regimen, therapeutic window, preclinical & clinical study design optimization, choices for combination treatments, and more. • Our team of highly qualified scientists is experts in the diverse set of quantitative techniques, including population PKPD modeling, model-based meta-analysis, quantitative systems pharmacology, joint modeling, agent-based modeling, and machine learning, with the modeling experience in various therapeutic areas, such as oncology, immuno-oncology, cardiovascular and metabolic diseases, neuroscience, respiratory and infectious diseases. • Our deep scientific and technical rigor is demonstrated in our publications, in peer-reviewed disease-domain journals.

SD2-225, Second Floor, DSP Laboratory Complex, Dubai Science Park Dubai, United Arab Emirates, 00000 United Arab Emirates Modeling and Simulation Decisions FZ LLC is an independent modeling consultancy. Our objective is to provide model-informed drug development solutions for global pharmaceutical companies and biotech start-ups. • We support decisions-making across the entire R&D pipeline by addressing the recurring questions on compound selection, dose & regimen, therapeutic window, preclinical & clinical study design optimization, choices for combination treatments, and more. • Our team of highly qualified scientists is experts in the diverse set of quantitative techniques, including population PKPD modeling, model-based meta-analysis, quantitative systems pharmacology, joint modeling, agent-based modeling, and machine learning, with the modeling experience in various therapeutic areas, such as oncology, immuno-oncology, cardiovascular and metabolic diseases, neuroscience, respiratory and infectious diseases. • Our deep scientific and technical rigor is demonstrated in our publications, in peer-reviewed disease-domain journals.

Office No: 1303, Building No: P/1341, Plot No: C-87 Electra Street, behind Honda Showroom Abu Dhabi, UNITED ARAB EMIRATES

The Offices World Trade Center Level 17, Office 1745 Central Market, Al Markaziya Abu Dhabi, United Arab Emirates At Truven Health Analytics™, our purpose is to make healthcare better — lower costs, improved quality, better results. Simple words. Yet remarkably complex concepts. But that's not stopping us. Or our customers. Every day, we get to work with smart, passionate professionals, from every facet of the industry, as they manage change and implement strategies that will achieve exactly those outcomes. Our customers are healthcare payers and providers. In both the private and public sectors. They're researchers and suppliers. Regulators. Movers and shakers in each piece and part of the healthcare world. With this broad view of healthcare, we're able to see when new challenges are just beginning to emerge. And that's when we begin working on new solutions. Data. We're driven by it. Known for our exacting collection and secure management of data, we've worked with clinical evidence, claims, clinical, and other healthcare data for more than 40 years. We know the challenges to watch for, what to do about them — and how to recognize new ones. Like finding new ways to measure risk for providers who take on more of it, and payers who contract for it. Or integrating data to deliver the solutions today's converging healthcare interests demand. Analytics. Because data alone is just numbers and letters. The need for reliable insights from data demands proven analytics. Our methodologies and algorithms are uniformly trusted across the industry to deliver critical information that leads to confident decisions. Coupled with flexible reporting, integration, and consulting services, our sophisticated analytics enable our customers to make their part of healthcare better, faster. Domain expertise. We have it. We really have walked in our customers' shoes. We've worked in their environments. That level of understanding, plus our leading data management capabilities and advanced analytics, are why our customers turn to us as their partner to deliver quality, reduce costs, and yield greater value in healthcare.

G-01, Building # 14, Dubai Internet City P.O.Box 500041, Dubai United Arab Emirates Visual Sparks Technologies offers IT solutions and clinical trial services.

Dubai, Dubai United Arab Emirates Visual Sparks Technologies offers IT solutions and clinical trial services.

Dubai Silicon Oasis Dubai United Arab Emirates Wacker offers contract manufacturing, biologic analysis, and quality control/assurance services.

Dubai, Dubai United Arab Emirates Advanta is an agronomic and vegetable seed company with a 20 year track record of success and growth. Advanta Limited is the holding company for the global business of Advanta. We have direct operations in India, Australia, Argentina and Thailand. We have exports of our products going into 25 more countries. United Phosphorous Ltd., a large Indian group in the global Agro Chemical sector, acquired Advanta in February 2006. Advanta Limited is now a member of the UPL Group of companies. In the month of April 2007 Advanta completed a very successful IPO. Advanta is now listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) in India. We have unique, superior and proprietary germplasm. This, combined with technology and bioscience capability gives us a robust platform for growth. Our experienced management team is ready to give a dynamic push to the aggressive growth plans we have. While continuing with traditional breeding principles, we have over the years successfully adopted the latest technological innovations to fast track our crop research. Dihaploid and Molecular Marker technology are some of the technologies we have successfully adopted in our crop improvement programs. We have entered into strategic alliance with some of the leading and high quality technology innovation companies across the world for value added biotech traits like pest resistance, herbicide and drought tolerance. Advanta is now embarking upon a very aggressive growth strategy. While organic growth will be a key factor in this, strategic acquisitions will play a crucial role in achieving our objectives set for the next five years.

Office 104, plot No: 258-615 Al Quoz 3rd, Dubai, UAE Akay is a leading global supplier of paprika and spice oleoresins from India.

Site Information

The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.

We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.

Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.

Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.

What is Scientist.com?

Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.

How can I use Scientist.com?

Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at   [email protected] or go to our website   www.scientist.com to speak to someone via our live chat.

Why should I place my order through Scientist.com?

Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.

How do I get my organization listed on the map?

If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.

Information about my organization is incorrect, how do I fix it?

Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.

Mission & Value

• Sites selection
• Feasibility
• Regulatory submissions
• Project Management
• Medical Writing
• Pharmacovigilance
• Training & Quality Assurance
• Staff Outsourcing

With 140 employees and more than 300 clinical trials performed in over 35 countries, MCT is the leading CRO in MEA region (Middle-East & Africa) and Pakistan. Working with many international pharmaceutical & biotech companies from all the globe (US, Europe, Asia) we are the renowned expert of MEA and Pakistan, enabling us to guide you through each country specificities (regulatory process, patient flow, health care system) and select the best sites for your clinical trials. Our experience in clinical trials in the region is wide and unique: infectious disease (including COVID 19), tropical disease, hematology, rare disease, cardiology, oncology, diabetes … MCT is your partner of choice for MEA and Pakistan.

WHY CHOOSE US

We support our sponsors with our local expertise of MEA and Pakistan: optimized startup (site selection & regulatory submission) and site management (proximity, cultural understanding, privileged communication).

MCT is the only CRO covering the whole MEA region and Pakistan through its own staff and local offices. We have developed a unique knowledge of the filed, making MCT the EXPERT of these regions.

MCT team is very experienced at all levels: Clinical Project Leads, Regulatory Officers, CRAs. Our team is made of professionals combining international experience with local expertise. They are MCT best value, contributing every day, by their skills and knowledge, to the success of your clinical trials.

MCT spirit and value are focused on Rigor, professionalism, respect of Deadline and above all: Client satisfaction

• Book appointment
• Hospitals & Clinics
• Specialities
• Patient Portal

• Important notice

Mediclinic International is aware of a fake social media post that is being circulated requesting users to engage with a Medical Feedback Reward Survey. Mediclinic has not circulated any such survey. The social media post has not been published by Mediclinic. Mediclinic advises that people do not engage with the survey or respond. We release all our official communications on our website and our official social media channels .

• Mediclinic Middle East
• Stay Services & Hospitals - Mediclinic Middle East
• Clinics & Hospitals in Dubai & Abu Dhabi - Mediclinic
• Health Knowledge
• Services and Specialities
• Mediclinic Health Packages
• Careers at Mediclinic Middle East
• About Mediclinic Middle East
• Media and News
• Mediclinic Middle East - Referring Doctors
• Mediclinic Middle East - Careers at Mediclinic
• Mediclinic Middle East Special Offers
• Mediclinic Baby - Prenatal, Maternity & Antenatal Care
• Privacy Statement
• Terms of Use
• Mediclinic Emergency
• Mediclinic Middle East - Health Insurance Partners
• What you should do in an emergency

Clinical Research in The Middle East - Mediclinic

• Pharmacy Home Delivery
• Mediclinic Kids
• Mediclinic Middle East - Book an Appointment with Our Doctors
• Mediclinic Precise - Genetic Testing & Profiling
• Mediclinic at Home
• Bourn Hall Fertility Centre
• Ayadi Homecare, أيادي للرعاية الصحية المنزلية
• Quality healthcare services in the comfort of your home
• Patient Privacy Notice
• Experience Cutting-Edge Healthcare at Mediclinic UAE - Health Experience Hub
• Client Experience Hub
• Genetic Health
• Travel Clinic
• Travel Vaccination Services at Mediclinic UAE

Mediclinic Middle East is one of the very few private healthcare organisations in the UAE to actively support its clinician’s research endeavours through medical research centres in the UAE. The number of facilities at Mediclinic Middle East provides access to a wide variety of patients and therapeutic areas. MCME has established a Research office to engage research opportunities that can substantially impact patients’ wellbeing. 

The Corporate Research Office is dedicated to the following:

• Ensure that all the research projects carried out at MCME are approved by the internal Research and Ethics Committee as well as the local Regulatory Authorities prior to initiation
• Contact point for Clinical Research Organisations and sponsors
• Provide support to the MCME research teams 
• Monitor and evaluate ongoing research
• Manage clinical research project budgets
• Provide Good Clinical Practice (GCP) training to MCME Research teams
• Ensure patient safety throughout all clinical trials 

MCME Research Brochure

PDF | 1.18 MB

Research Studies

Workflow Process

Mediclinic Middle East Research Office follows specific guidelines to ensure that clinical research is carried out ethically and adds real value to the scientific community.

Our Publications

Dr. Adrian Stanley Chief Academic Officer

Dr Rakshinda Mujeeb Research Projects Manager Rakshinda.Mujeeb@mediclinic.ae

Ms. Zineb Katache   Research Assistant Zineb.katache@mediclinic.ae

Mediclinic Middle East Research Office Mediclinic Corporate Office, Dubai Production City, Publishing Pavillion, Level 6, PO Box 123812, Dubai UAE. Contact Email:  MCME-ResearchOffice@mediclinic.ae

Mohammed Bin Rashid Medical Research Institute

Pioneering the Present, Healing the Future

Mohammed Bin Rashid Medical Research Institute, an initiative of Al Jalila Foundation, is a world class biomedical research institute strategically located in the heart of Dubai Healthcare City next to the Mohammed Bin Rashid Academic Medical Center which houses the Mohammed Bin Rashid University for Medicine and Health Sciences, ensuring seamless collaboration in the academic, healthcare and scientific community.

The UAE’s first independent multi-disciplinary medical research centre aims to bring together leading local and international scientists to work together to discover solutions for the region’s biggest health challenges: cancer, cardiovascular disease, diabetes, obesity and mental health. In April 2020, Al Jalila Foundation expanded its research portfolio in response to the novel coronavirus (COVID-19) outbreak with dedicated research grants to address the pandemic and infectious diseases.

The centre has a goal to collaborate with renowned research institutions around the world to foster international scientific collaborations, nurture home-grown biomedical researchers and introduce best practices in the region.

The AED 300 million not-for-profit research centre is fully funded by Al Jalila Foundation, a global healthcare philanthropic organisation, to fulfill its vision to transform lives through medical education and research, as a beacon for medical innovation in the UAE and the region.

Al Jalila Foundation encourages ground-breaking research through specialist knowledge, expertise and resources across a range of scientific disciplines to support regionally-relevant medical advancements. We offer a number of funding schemes, including seed grants, international fellowships and collaborative research opportunities in our 5 research focus areas. The investments we make today will pioneer the cures of tomorrow.

Al Jalila Foundation, a global philanthropic organisation dedicated to transforming lives through medical education and research, was established by His Highness Sheikh Mohammed Bin Rashid Al Maktoum, Vice-President and Prime Minister of the United Arab Emirates (UAE) and Ruler of Dubai in November 2012, to position Dubai and the UAE at the forefront of medical innovation.

Since 2014, Al Jalila Foundation has invested AED 28 million in 100 scientific research projects at 15 institutions to advance biomedical research in the UAE.

For more information on our research grant programme  click here .

For more information on our funded research projects click on the links below.

Al Jalila Foundation Research Grants Portfolio 2020

Al Jalila Foundation Research Grants Portfolio 2018

Al Jalila Foundation Research Grants Portfolio 2017

Al Jalila Foundation Research Grants Portfolio 2016

Al Jalila Foundation Research Grants Portfolio 2014-2015

Make a Donation

When you donate you are not only giving a gift, you are giving the gift of life. Transform someone’s life today and help us heal our society, one donation at a time. With your support, no solution is out of sight or out of reach.

• Asia-Pacific
• Middle East & Africa
• The Pharma Legal Handbook
• Regulatory, Pricing and Reimbursement
• Marketing, Manufacturing, Packaging and Labeling
• Preclinical and Clinical Trials
• Op-Eds & Contributions
• White Papers

Clinical Research in the UAE: Quickfire Progress & The Road Left to Travel

With cutting-edge hospital infrastructure being put in place, government authorities rolling out evermore supportive regulatory upgrades, big pharma championing ‘clinical trial diversity’ with greater non-Caucasian representation in trial cohorts, and a high regional prevalence of genetic diseases, it seems that the stage is set for the UAE to assume a much more prominent role in global clinical research. But is it that simple, and what needs to be done next for the Emirates to truly achieve clinical trial hub status?

Challenging Beginnings

Only one percent of global clinical trials take place in the Middle East and Africa, a number which reflects neither the size of the region, the burden of illnesses that its 1.5 billion-plus population carries, or the medicines they consume. Global biopharma has traditionally situated the in-human testing of its latest molecules in the US and Europe with their large and willing patient populations, closer to headquarters, hospitals and universities with the expertise to carry out such trials, and marketplaces with the financial means to absorb any products that emerge from them.

Even in the region’s most developed markets, like the UAE, challenges abound. Mohamed Mostafa, CEO of full-service MEA-focused clinical research organisation PDC CRO notes that “the UAE’s small population size is a challenge. Additionally, most of the people here are expats, and because they are travelling here for work, they are generally in good health. Also, the population is 70 percent male, so women-specific studies or gender-diverse research becomes more challenging.”

Mostafa continues, “Having worked for Big Pharma companies, I know that headquarters’ decision making around site allocation is based on two areas: operational and strategic. Operationally we are fine in MEA, with a diverse population, rapid site activation, good infrastructure, and strong regulatory bodies. Where we struggle in most of the region is on population and commercial market size. Nevertheless, if we do have a pool of patients, like in rare diseases, it is a lot easier to convince pharmaceutical companies to partner with us here.”

MSD GCC Managing Director Ashraf Mallak adds that “There are several reasons why MSD did not have a clinical footprint in the GCC in previous years. Some of the external reasons include the need for a large population, a large number of patients to conduct trials, as well as an established research infrastructure.”

Changing Times

However, spearheaded by the UAE and its ambitious attempts to climb the biopharmaceutical value chain, there are now hopes that MEA can become a more significant contributor to global clinical research efforts.

Mallak points out that “things are changing. Last year we signed an agreement with the Department of Health of Abu Dhabi (DoH) to start exploring observational research in the UAE. We invited our Global Clinical Research Team for a visit to Abu Dhabi to assess preparedness for clinical trials which showed great promise due to the diversity of the UAE population, the high calibre of the healthcare infrastructure and institutions, the talent and competence of researchers with vast international experience as well as the regulatory environment of the UAE.”

The physicians within MEA have sufficient experience and knowledge gained from working and studying in Europe and the US, the right patient pools exist, and a good enabling infrastructure is there Hassan Herrou, CSL Behring

Hassan Herrou, general manager for MEA at CSL Behring , which holds a significant portfolio of rare diseases therapies, sees strong fundamentals in place, at least in his company’s therapeutic areas of focus. “The physicians within MEA have sufficient experience and knowledge gained from working and studying in Europe and the US, the right patient pools exist, and a good enabling infrastructure is there. Therefore, there is a fantastic opportunity for CSL Behring to take the next step and conduct more multicentre clinical trials in the region.”

Others foresee more clinical trials coming to the region as part of the UAE government’s drive to achieve life science hub status. “The next stage in the country’s life sciences development, besides being a base for regional headquarters, will be greater investment in innovation and R&D, as APAC hubs like Singapore have already done, to propel the UAE forward,” says Samir Khalil, executive director of PhRMA MEA . “When choosing where to situate a clinical trial, industry sponsors are looking for a favourable ecosystem, which I think the UAE can work on further to attract a proportion of these global trials.”

Finding the Niches

There seems to be broad stakeholder alignment that, with a population of under 10 million, the UAE must focus in on specific niches to compete as a trial destination. “While the population is relatively small, the UAE could be a base for late-stage trials, which have a strong medical impact as well as an impact on employment and the overall economy,” says Khalil.

The Dubai Science Park’s Senior Vice President Marwan Abdulaziz Janahi continues, “We are seeing a growing number of late-stage clinical trials being carried out in the UAE, with the aim of providing access to treatments. This is particularly true for rare diseases, as the Middle East has a higher percentage of patients affected by such diseases than other regions. Several established pharmaceutical companies are investing in rare disease treatments, with companies such as AstraZeneca, which recently acquired Alexion, seeking to identify and treat patients in the region as part of their market access strategy. This is a highly positive trend.”

We are seeing a growing number of late-stage clinical trials being carried out in the UAE Marwan Abdulaziz Janahi, Dubai Science Park

PDC CRO, which predominantly focuses on infectious diseases, metabolic disorders, and rare conditions, has been able to count on support from the authorities to fuel its clinical research output, especially in the paediatric space. “We have a lot of expertise in genetic, haematological, and neurological disorders, with the majority being paediatric-related,” notes Mohamed Mostafa. “It is especially important that these younger patients are diagnosed early as quick access to therapies gives them a big advantage later in their lives. This is all being fuelled by the government and the Al Jalila Hospital, the leading paediatric hospital in the UAE. We have even been able to conduct trials that involve patients from outside the UAE by having them referred for treatment here.”

Mostafa adds that “many of the trials we do here are extremely complex. The region is typically considered to be a rescue region, as when companies cannot find patients across the world they come here as a last resort. This means we are well prepared and are ready for simpler clinical trials in the future.”

Regulatory Upgrades

An ecosystem of supportive policies and regulations will be crucial if the UAE is to take the next step in its development towards clinical trial hub status. Positive steps have already been taken in this direction, as Mohamed Ezz Eldin, who heads up Novartis operations in the Gulf region , notes.

We have worked hard to ensure our regulatory framework fosters innovation and progress, whilst maintaining exceptional standards of quality and safety Noura Al Ghaithi, Abu Dhabi DoH

“For a country to attract more R&D investments in areas like clinical trials, it is important to have a supporting regulatory framework to encourage private sector involvement,” says Ezz Eldin. “The UAE is attracting experts to the country by having the right infrastructure in place, collaborating with universities and institutes, and setting up clinical trial centres which will strengthen its position as a clinical trial centre in the region.

PDC CRO’s Mostafa is in accordance, adding that “the UAE government, particularly the Abu Dhabi DoH, has accelerated the development of clinical studies. They have overseen what we are doing and appreciate the importance of building a legitimate ecosystem that meets international regulations.”

The Abu Dhabi DoH’s own undersecretary, Noura Al Ghaithi , proclaims that “We have worked hard to ensure our regulatory framework fosters innovation and progress, whilst maintaining exceptional standards of quality and safety. This has included streamlining the approval process for clinical trials. It takes no longer than 28 days between trial submission and approval which has led us to see a rapid expansion in clinical trials, with a staggering increase in the number of clinical trials conducted locally between 2021 and 2022 – an increase year-on-year of 484 percent.”

The COVID Push

The COVID-19 pandemic and the subsequent rush to test therapeutics and vaccines in record time also had a big effect on the way in which the UAE, and the wider region, conducts and approaches clinical research. “During the pandemic, we adjusted approval timelines to be part of global clinical trials to develop vaccines in collaboration with the US, China, and Russia,” says the Dubai Science Park’s Abdulaziz Janahi. “In just two years, we streamlined our regulatory process, making it more robust and efficient, creating a strong foundation to accelerate innovation.”

COVID-19 was a massive catalyst for growth which has made people understand the importance of research Mohamed Mostafa, PDC CRO

PDC CRO has seen its own business as an outsourcing partner for clinical research booming post-pandemic. “COVID-19 was a massive catalyst for growth which has made people understand the importance of research,” states Mostafa.

“Our clinical studies within this area have given confidence to pharmaceutical and biotechnology companies to conduct more research and partner with us in the region,” he says. “We partner now with many top 20 pharmaceutical global players through master services agreements or partnerships. Also, we have direct access to biotechnology companies and support them in their programs of clinical development through Phases I, II and III, with clients from the US, Europe, and Asia Pacific.”

While admirable progress has already been made in boosting the UAE’s clinical research output, there remains a long road to travel before the country can call itself a true global heavyweight in the field. For Abdulaziz Janahi, the ultimate goal for the UAE is becoming more than just a global node in the drug development process of innovations emanating from abroad, but instead bringing its own products to market.

“We need to focus on pushing ideas that are being developed at local universities from the lab bench to the market,” he says. “This is a long-term objective that cannot be achieved overnight, as it requires the development of capabilities and talent. I believe this will take place within the next five to ten years but is crucial to take the right measures to ensure it does so.”

Patrick Burton

Related articles, uae enabling innovation in the uae: incentives, regulatory policies & ip rights protection, uae middle eastern sovereign wealth funds continue pharma investment push, uae the long read: the uae – raising its game, latest report.

Related Content

Other topics.

See our Cookie Privacy Policy Here

How can we help?

Select type, request an appointment.

*Disclaimer: Your appointment will only be confirmed after our customer service representative contacts you.

• Research & Innovation Hub

Our landmark initiative: First AI-led research lab in the region

As a premier healthcare institution, American Hospital Dubai doesn’t believe in just expanding the boundaries of care delivery by combining world-class expertise with advanced medical technology; but in also directly investing in healthcare research and innovation for the greater good of mankind.

In our journey towards achieving more milestones in medical care, we have aligned ourselves with the vision and strategy of the UAE Government to use the power of AI to help minimize the burden of chronic diseases for the welfare of our citizens and residents. Our AI approach strived to develop scientifically proven, relative and explainable AI models that support our clinical operations and outcomes.

We believe that our responsibility as a leader in the field calls upon us to lead by example where we have partnered with Cerner, a global healthcare technology company, to set up the first Artificial Intelligence-led healthcare research lab in the region. The AI data lab will leverage Jupiter notebook Python and R as the data science environment, combined with Cerner’s Data Lab and its intelligent predictive models that have been built, trained and localized. This program will strive to achieve a quadruple aim (patient, caregivers, financial and outcome/value driven results).

The research lab will help American Hospital Dubai understand the healthcare needs of the people in the UAE with greater insight, through an enhanced predictability of disease patterns, thus taking us closer to our objective: to continue to redefine a patient-centric healthcare delivery system and empower individuals to proactively manage their health.

The AI-led research center will also promote the critical requirements in today’s global healthcare landscape: regional and global collaborations and expansion. As the pandemic has proved, when it comes to healthcare challenges, there are no borders.

Our research center’s already delivering results

Our Cerner collaboration, for example, has helped us devise a COVID-19 Model on Patient Mortality and ICU Admission Prediction.

How did we achieve that? AI-led algorithms helped us to identify patients who are at high risk for ICU admissions and risk of mortality and this helped us to provide them with timely and appropriate care. We looked at more than 5,000 attributes, analyzed the top 50 risk identifiers across the globe and analyzed a 100K combination of identifiers for American Hospital Dubai’s patients, to arrive at an accurate identification of the top 10 features that will impact the outcome for COVID-19.

The result? Improved clinical outcomes and focused personalized patient care. Not just that, it also means that we can actually reduce the numbers of ICU admissions and mortalities, easing the pressure on cost and infrastructure. This is one concrete example of how AI plays a vital role in improving healthcare.

Oracle partnership: Excellence in non-clinical domain

World events have proven the need for foundational enterprise business capabilities that enable agility. We believe having a clear ERP strategy is a must to engage business leaders and deliver capabilities that enable our organization to survive and thrive. This approach will help us deliver innovations quickly and be able to adapt applications dynamically. Our partnership with Oracle will help us implement a composable enterprise with the digital transformation strategy where it will help us innovate and adapt to the changing needs of the business.

In the healthcare setting, we see the impact of these new technology trends to extend the quality of patient care while reducing costs by removing bottlenecks in growth and enhancements. We believe we will be able to eliminate information silos, provide comprehensive view of operations, improves process efficiency, and enhance patient care.

A healthcare institution is as much about delivering excellent care as it is about having great workflow processes, highly motivated staff, enhanced productivity, and a progressive management.

American Hospital Dubai is consistently seeking advanced next-gen technology and process trends to improve its own efficiencies in everything it does. Its partnership with Oracle Cloud Applications and Cerner Corporation for its major digital transformation programs will further integrate its business and clinical aspects and provide the foundation for predictive analysis capabilities, to assist administrators , clinicians to make strategic plans that can improve organizations’ overall efficiencies, patient experience and clinical outcomes

Cerner’s new health IT platform, electronic health record (EHR), will improve the safety, quality, and healthcare experience for patients and caregivers. Oracle’s digital business platform and Oracle Enterprise Resource Planning (ERP) Cloud will enhance productivity, reduce costs, and improve controls. Together, the two will integrate the hospital’s business and clinical operations to improve patient care systems, reduce costs through efficiency, promote higher productivity and performance, boost employee satisfaction and streamline workflow systems by offering real-time data.

We believe in investing in all these objectives to further strengthen our stature as a beacon of medical service excellence and expertise in the region and beyond.

• United Arab Emirates
• Emirate of Dubai
• Clinical Research

Clinical Research jobs in Dubai

Luxury clinic senior aesthetician (dubai relocation).

Nurse with Beauty Clinic Experience

Clinical Psychologist (Child & Adolescent) Innovations Group

Senior Clinical Dietitian 2

Specialist Clinical Hematologist

Dental Clinic Manager - Dubai

Research Assistant Innovation and Digital Health

Clinical Application Specialist

Business Head Clinical lab

Long Beach CA - Clinical Research Coordinator - Apply

Clinical Research Coordinator - Apply

Clinical Research Nurse - Apply

Senior Clinical Research Associate | Ora Inc. Dubai

Clinical Research Associate - Apply

Clinical Research Assistant - Apply

• Clinical Research Associate

Are you looking for a Clinical Research job in the Dubai? Whether you’re an experienced job-seeker or have never looked before, you may be asking yourself where to start.

This area has been home to many long-standing businesses as well as several modern companies such as digital media, engineering and industrial services.

If living and working in Dubai is something that excites you, then the following article will provide some tips on how to locate available job opportunities in this vibrant metropolitan conurbation. We'll discuss the various sectors that exist, local employers who are recruiting now and different means of searching for roles online.

What do Clinical Research do?

Clinical Research is responsible for providing a range of services to the people of Dubai, including education, social care, housing, planning and economic development. It works closely with local businesses and other organisations to ensure that the area remains prosperous and attractive to visitors.

Clinical Research provides a wide range of services to its residents, including job search advice, training and development opportunities, and help with finding suitable accommodation.

Where can I find Clinical Research jobs in Dubai?

There are a variety of ways to search for jobs in Dubai. The most popular method is to use online job boards such as Jobsora. We allow you to filter your searches by location and sector so that you can easily find roles that match your skills and experience.

You can also search for jobs on the Dubai local job websites, which lists all current vacancies in the area. Additionally, you can contact local employers directly to enquire about any available positions.

Finally, there are a number of recruitment agencies based in Dubai that specialise in finding people to work in the area. These companies often have access to exclusive job opportunities that are not advertised elsewhere.

In conclusion, there are a variety of ways to find Clinical Research jobs in Dubai. Whether you’re looking for a permanent role or something more flexible, the borough has plenty of opportunities available. With the proper research and preparation, you can easily locate the perfect job for you.

How much do Clinical Research in Dubai get paid?

Clinical Research in Dubai are elected representatives of the local community, and they are paid an annual allowance for their work. The amount of this allowance is determined by the Independent Remuneration Panel for Dubai, which reviews the allowances every four years.

• Emirate of Abu Dhabi
• Emirate of Sharjah
• Emirate of Ajman
• Saudi Arabia
• Jobs in Emirate of Dubai
• Jobs in Dubai
• Clinical Research jobs
• other locations
• clinical research nurse
• clinical research coordinator
• clinical research assistant
• clinical research physician
• quantity surveying
• online procurement
• loan servicing
• bar supervisor
• erp consultant
• bid consultant
• hygiene officer
• chemistry and biology
• drill rig operator

• ICH GCP (De)
• ICH GCP (En)
• ICH GCP (Es)
• ICH GCP (Fr)
• ICH GCP (It)
• ICH GCP (Pt)
• ICH GCP (Ru)
• AUSTRALIA (NHMRC)
• JAPAN (PMDA)
• US Clinical Trials Registry
• EU Clinical Trials Registry
• Pharmaceutical Companies
• Clinical Research Labs
• Service Companies
• Clinical Research Events
• Publications
• Researchers

RAY-CRO in United Arab Emirates

Web:   https://www.ray-cro.com/

Phone:   +971525964578

• Contract research organizations
• United Arab Emirates

Dubai Science Park, Office 1004, Dubai, UAE

Other RAY-CRO's locations around the world

• Saudi Arabia

About RAY-CRO

RAY is a regional full-service contract research organization with extensive experience in the management of clinical trials across a broad range of therapeutic areas.

RAY was established in Feb 2010. Company services:

• Clinical Operations
• Clinical Data Management
• Pharmacovigilance
• Patient Support Programs
• Medical Affairs Services and Trainings
• Regulatory Affairs
• Medical Translation
• Biostatistics
• Medical Writing
• Pharmaco-economics Services
• Trainings and Workshops
• Mobile Nursing
• Quality Assurance and Auditing

List of CROs by location

• Bosnia & Herzegovina
• Czech Republic
• Netherlands
• Switzerland
• United Kingdom
• Dominican Republic
• El Salvador
• Saint Lucia
• Trinidad & Tobago
• United States
• Philippines
• South Korea
• Turkmenistan
• Burkina Faso
• Congo, DR of
• Cote d'Ivoire
• Equatorial Guinea
• South Africa
• New Zealand
• Papua New Guinea

• [email protected]
• Head Office - Beirut

Clients & Partners

We are proud to manage some of the leading global and regional brands.

Phoenix Clinical Research is a regional dynamic full-service Contract Research Organization (CRO) established in Lebanon. Its objective is to cover the whole Middle East and North Africa region.

Our Services

A full service regional Contract Research Organization.

Medical Writing & Biostatistics

Whether you need support in clinical and observational studies or communications...

Project Management

We ensure that our project managers have the proper knowledge and skills to successfully manage your...

Clinical Operations

On most of the projects we have managed in the Middle East region, we have developed specific recruitment...

Pharmacovigilance

A short description of the service and how the visitor will benefit from it.

Why Phoenix CR?

Phoenix Clinical Research is one of the very few full service CROs in the MENA region that is ISO accredited.

Phoenix Clinical Research combines the flexibility and responsiveness of its structure coupled with more than 18 years of international and regional expertise.

Phoenix CR was the first Clinical Research Organization (CRO) to monitor a Phase I study in Egypt.

Our team helped rescue several clinical trials in the region after handover from other international and regional clinical research organizations (CROs).

We are very known for the quality of our deliverables as we aim to bring the Swiss standards to the Middle East.

Have a Look at Our Latest News

Provided by Department of Health – Abu Dhabi, Innovative Gene Transfer Therapy Administered For Duchenne Muscular Dystrophy for First Time in Abu Dhabi

  Department of Health – Abu Dhabi (DoH) has provided revolutionary gene transfer therapy for Duchenne muscular dystrophy for the first time in the emirate. The treatment was carried out at Sheikh Khalifa Medical City (SKMC), part of SEHA, a subsidiary of PureHealth, reflecting Abu

ILIKOS Consulting Group and PHOENIX Clinical Research Announce Strategic Partnership

As the timeframe to develop a new therapy or technology is increasing along with competitive and high-risk nature of the industry, exploring emerging regions that offer better Patient access while maintaining regulations and standards for clinical research has become a necessity. Entering new regions is

Challenges of the MENA region and how we overcome them

Challenges of the MENA region and how we overcome them Conducting clinical trials in the Middle East and North Africa (MENA) region offers a multitude of opportunities, yet it also presents unique challenges that biotech companies must carefully navigate. Understanding and effectively addressing these challenges

Why MENA Region

• Ideal to conduct genetic studies with high rates of consanguinity that could reach 70% in certain regions.
• Western lifestyle habits increased the prevalence of cancer, cardiovascular and metabolic diseases.
• GCC countries have the second highest prevalence of type 2 diabetes worldwide.
• It has the highest incidence of pulmonary infections in the world.
• Study start-ups can be achieved in less than three months in some countries.
• The majority of investigators and study site staff are fluent in English.
• Many Middle Eastern hospitals have been granted the Joint Commission International Accreditation.
• The increase in life expectancy.

© 2024 All Rights Reserved. Design by Pixelated